Dipal Doshi is CEO & President at Entrada Therapeutics, Inc. (TRDA). They have made 5 open-market trades across 1 company since 2015, most recently 2026-09-02.
CIK 0001613084
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TRDA | SELL · 10b5-1 | 2024-07-12 | 2024-07-16 | $17.84 | $34K | -1.7% | -7.1% | +1.8% |
| TRDA | SELL · 10b5-1 | 2024-06-13 | 2024-06-14 | $16.17 | $16K | -9.0% | +14.7% | -4.6% |
| TRDA | SELL · 10b5-1 | 2024-05-16 | 2024-05-20 | $15.04 | $45K | +1.1% | -5.6% | +8.0% |
| TRDA | SELL · 10b5-1 | 2024-02-15 | 2024-02-20 | $15.00 | $15K | +1.4% | +0.0% | +13.1% |
| TRDA | SELL · 10b5-1 | 2024-01-16 | 2024-01-18 | $15.99 | $16K | +2.1% | -9.4% | -18.7% |
| TRDA | SELL · 10b5-1 | 2023-12-20 | 2023-12-22 | $15.00 | $15K | -8.5% | -6.0% | -18.8% |
| TRDA | SELL · 10b5-1 | 2023-11-13 | 2023-11-13 | $16.23 | $16K | -32.4% | -19.2% | -10.8% |
| TRDA | SELL · 10b5-1 | 2023-10-17 | 2023-10-19 | $15.00 | $15K | +8.6% | +10.7% | +5.2% |
| TRDA | SELL · 10b5-1 | 2023-09-13 | 2023-09-15 | $15.00 | $15K | -6.4% | -10.4% | -15.5% |
| TRDA | SELL · 10b5-1 | 2023-08-14 | 2023-08-16 | $15.67 | $16K | +5.7% | +5.6% | +6.9% |
| TRDA | SELL · 10b5-1 | 2023-04-27 | 2023-05-01 | $13.71 | $27K | -2.9% | -8.4% | +38.8% |
| TRDA | SELL · 10b5-1 | 2023-04-17 | 2023-04-19 | $18.01 | $38K | -15.0% | -17.3% | +17.2% |
| TRDA | SELL · 10b5-1 | 2023-03-27 | 2023-03-29 | $14.72 | $29K | +0.7% | -21.9% | -18.2% |
| TRDA | SELL · 10b5-1 | 2023-02-28 | 2023-03-02 | $12.00 | $24K | +31.6% | +47.1% | +10.9% |
| TRDA | SELL · 10b5-1 | 2023-01-27 | 2023-01-30 | $12.00 | $24K | +27.2% | +0.0% | +4.2% |
| TRDA | SELL · 10b5-1 | 2023-01-09 | 2023-01-10 | $15.02 | $36K | -6.6% | +3.9% | -1.6% |
| TRDA | SELL | 2022-12-27 | 2022-12-29 | $15.02 | $423K | -1.5% | -12.4% | +6.2% |
| TRDA | SELL · 10b5-1 | 2022-11-28 | 2022-11-30 | $13.91 | $28K | +11.8% | -6.9% | -12.2% |
| TRDA | SELL | 2022-10-25 | 2022-10-27 | $20.69 | $509K | -11.7% | -35.2% | -36.2% |
| TRDA | SELL | 2022-10-20 | 2022-10-24 | $18.53 | $162K | +5.0% | -30.4% | -32.8% |
| TRDA | SELL | 2022-09-26 | 2022-09-28 | $15.20 | $213K | -6.4% | +44.7% | -3.7% |
| TRDA | SELL | 2022-09-21 | 2022-09-23 | $15.11 | $118K | -11.3% | +24.6% | -2.7% |
| TRDA | SELL · 10b5-1 | 2022-09-15 | 2022-09-19 | $15.04 | $3K | +16.0% | +28.7% | +48.4% |
| TRDA | SELL · 10b5-1 | 2022-09-08 | 2022-09-12 | $15.13 | $27K | +9.3% | +18.1% | +32.1% |
| TRDA | SELL · 10b5-1 | 2022-08-29 | 2022-08-31 | $12.72 | $25K | +3.8% | +24.5% | +11.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.